Audit a pharmaceutical contract manufacturer in China by first verifying the named legal entity, site and current relevant scope, then assessing product-to-train fit, quality-system evidence, technology-transfer and co-manufacturing controls, testing and release interfaces, and the written governance model. Public profiles and licences support screening but cannot establish product-specific fit, capacity, regulatory outcome or project acceptance. Use a risk-based, project- and market-specific review before sensitive disclosure and final agreements.
A China contract-manufacturing audit should begin with the current NMPA framework and the precise project scope. It is not a substitute for destination-market diligence: the target country's filing, inspection, testing, import, release and lifecycle obligations must still be mapped separately.
1. Establish the audit scope before the visit
Set the decision that the audit must support: initial screening, technology transfer, commercial manufacture or a change assessment. Identify the legal entity, physical site, dosage form and project stage, the intended market, and the proposed division of regulatory and quality responsibilities. Without those anchors, an audit can become an unfocused collection of generic documents.
The National Medical Products Administration states that, before accepting commissioned production, a manufacturer should evaluate the marketing-authorisation holder and proposed product comprehensively, including the holder’s qualifications and quality-management capability, product risk, technology-transfer feasibility and feasibility of co-line manufacture; only after that evaluation should the parties sign the manufacturing and quality agreements.[1]
2. Verify legal entity, site and applicable scope
Confirm that the entity proposed in the contract is the entity responsible for the relevant site and activities. Review the current authorisation scope, address, dosage forms and any boundary that needs clarification. A brochure, a historic certificate or a third-party listing may support a preliminary screen, but it is not a conclusion about current scope or product-specific acceptance.
3. Review the quality system as operating evidence
Assess how quality assurance, quality control, deviations, CAPA, change control, complaints, recalls, suppliers, data and management escalation operate in practice. The focus is not whether a procedure exists, but whether roles, records, review cycles and risk decisions can be traced. The project’s risk profile should determine how deeply each area is assessed.
4. Test product and process fit
Map the proposed dosage form, formulation characteristics, process route, presentation, packaging, storage and scale range to the relevant manufacturing train, equipment, utilities, personnel, logistics and control strategy. A listed dosage form does not automatically demonstrate that every product in that category can be accepted. Product-specific assumptions must be confirmed through appropriate technical review.
5. Evaluate technology transfer and co-manufacturing risk
A transfer plan should identify accountable owners, gap assessment, training, protocol and report approval, change control, verification or validation, data review and decision gates. For shared facilities, examine how product and process risks are identified and controlled. For sterile or other higher-risk products, increase the depth of review of contamination-control arrangements, flows, utilities, monitoring, cleaning and verification evidence according to the actual project.
6. Define laboratory, release and data interfaces
Clarify who owns sampling, testing, OOS/OOT investigation, batch-record review, release support, stability, retains and original data. Confirm the expected access rights, timing and escalation route. A quality agreement should convert statutory and regulatory roles into a working responsibility matrix; it does not transfer away the responsibilities that remain with the relevant legal party.[2] [3]
7. Record findings as project decisions
A mature audit record does not stop at pass or fail. For each observation, record the observed fact, potential impact, affected project scope, accountable party, requested corrective evidence, due date and re-review method. This distinguishes gaps that can be responsibly closed before project start from risks that may change the cooperation route.
After the visit: define ongoing China-side oversight
For marketed-drug contract manufacturing covered by NMPA Announcement No. 134 (2025), plan ongoing China-side oversight as well as the initial visit. Section I(V) calls for manufacturer–MAH cooperation on quarterly risk assessment and annual product-quality review. For high-risk products such as sterile drugs, MAHs must assign personnel to supervise validation through on-site inspections at least once a year, including sterilisation-process validation and aseptic-process simulations.[1] This validation-oversight requirement is not a universal annual full-site audit rule. As a practical follow-up step, record responsible functions, evidence to review, the next review date and escalation triggers. Confirm applicability to the exact product and responsibility pathway; assess destination-market obligations separately.
CDMO site visit checklist: eight evidence questions
A useful CDMO site visit tests the proposed product and activity at the named site, rather than treating a facility tour as proof of suitability. Agree the permitted review scope and confidentiality controls in advance. For each question, record the source record or demonstration reviewed, the gap, its project impact and the owner of the follow-up. ICH Q10 calls for assessing the suitability and competence of parties before outsourcing, defining quality responsibilities in a written agreement, and monitoring performance afterwards.[4]
- Entity and scope: Which legal entity, physical site, licensed activities and proposed subcontractors would perform each step?
- Product-to-train fit: Which equipment, utilities, materials, storage conditions and controls are relevant to this dosage form and presentation?
- Quality-system records: Can the team show how deviations, CAPA, change control, complaints and data review work in practice, using suitably redacted examples?
- Transfer readiness: Who owns knowledge transfer, analytical-method transfer, gap closure, training, acceptance criteria and approval of protocols and reports?
- Contamination and cross-product risk: What risk assessment, segregation, cleaning, monitoring and verification evidence applies to the proposed route?
- Testing and release: Who performs sampling, testing, investigations, batch-record review, release support and retention of original data?
- Quality agreement: Are responsibilities, communication, change notification, audit access, escalation and subcontracting controls allocated in writing?[5]
- Closure decision: Which gaps must be resolved before technical transfer or supply, what evidence will close them, and who decides?
This is a planning checklist, not a claim that any named site has passed an audit. The FDA quality-agreement guidance cited here is US-specific; the final visit plan and decision must follow the product, site, market and applicable requirements.
A safe first-contact checklist
Before an NDA, a prospective partner can prepare a concise non-confidential summary of the dosage form, presentation, stage, target market, requested model (CMO, CDMO or technology transfer), scale range, timing and key decision points. Do not send patient information, formulas, full dossiers, detailed process instructions or trade secrets before an NDA and controlled disclosure plan are in place.
Frequently asked questions
What should a pharmaceutical CMO audit cover?
It should test the named entity and site, current scope, quality system, product fit, transfer readiness, co-manufacturing risk, laboratory and release interfaces, and governance. The depth is risk-based and project-specific.
Can a licence or capability presentation replace a CMO audit?
No. Public materials support screening, but cannot establish product-specific fit, current operating evidence or project acceptance.
What is safe to share before an NDA?
Share only a non-confidential project brief: dosage form, stage, target market, requested scope, presentation, scale range and timing. Protect formulas, full dossiers, patient information and trade secrets.
Does an audit guarantee project acceptance?
No. Final decisions require product-, site-, market- and evidence-specific review, together with written quality and commercial arrangements.
Authoritative sources
- NMPA: Announcement on Strengthening the Supervision and Administration of Commissioned Production of Drugs (2025 No. 134)
- Hainan Medical Products Administration: Measures on strengthening MAH responsibility and quality supervision for commissioned production
- NMPA: Regulation on marketing authorisation holders’ implementation of drug-quality responsibilities
- ICH Q10 Pharmaceutical Quality System, section 2.7: Management of outsourced activities and purchased materials
- FDA: Contract Manufacturing Arrangements for Drugs—Quality Agreements (2016)
Partial edit on 24 October 2026: Added ongoing China-side oversight; preserved the prior full-review date. This is not a new full-page source review.
This article is general industry information, not legal, regulatory or medical advice. It is not an assessment of any company, facility, product, market or project. Project suitability must be determined by the responsible parties using applicable requirements, product risk, audit findings and controlled technical information.